Related references
Note: Only part of the references are listed.A Developmental Taxonomy of Glioblastoma Defined and Maintained by MicroRNAs
Tae-Min Kim et al.
CANCER RESEARCH (2011)
Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres
Davide Sciuscio et al.
CLINICAL CANCER RESEARCH (2011)
A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2011)
Geriatric neuro-oncology: from mythology to biology
Michael Weller et al.
CURRENT OPINION IN NEUROLOGY (2011)
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
MGMT-Independent Temozolomide Resistance in Pediatric Glioblastoma Cells Associated with a PI3-Kinase-Mediated HOX/Stem Cell Gene Signature
Nathalie Gaspar et al.
CANCER RESEARCH (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
David M. Peereboom et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Epigenetic Deregulation of DNA Repair and Its Potential for Therapy
Monika E. Hegi et al.
CLINICAL CANCER RESEARCH (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography
Oliver Schnell et al.
NEURO-ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Patterns of Care in Elderly Glioblastoma Patients
Fabio M. Iwamoto et al.
ANNALS OF NEUROLOGY (2008)
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
L. Weinmann et al.
CELL DEATH AND DIFFERENTIATION (2008)
Stem cell-related Self-Renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
Anastasia Murat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy
Annechien Lambeck et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
J Wischhusen et al.
ONCOGENE (2003)
Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives
S Hirschfeld et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
